Mark Lagatta is a Nephrology physician. OpenAlex indexes 7 publications with 620 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4100 Metric Dr
Suite 200
Winter Park, FL 327926832
Telephone
407-681-8720Registry record last updated 23 Dec 2009.
Industry payments
41 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year202568 payments
- Amgen Inc.Program year20259 payments
- Mallinckrodt Hospital Products Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
72.9%Angiotensin receptor blocker (ARB)22.9%Losartan Potassium60%Olmesartan Medoxomil30%Valsartan3%Losartan-Hydrochlorothiazide2%Candesartan Cilexetil2%Filspari2%Part D<11 patientsLoop diuretic12.4%Bumetanide66%Furosemide29%Torsemide5%Part D≥70 patients+ 13 more classes in this area
Metabolism & gastrointestinal
12.4%Potassium supplement3.8%Potassium Chloride100%Part D≥42 patientsSGLT2 inhibitor2.4%Farxiga100%Part D≥21 patients+ 6 more classes in this area
Musculoskeletal
5%Xanthine oxidase inhibitor5%Allopurinol100%Part D≥42 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- An Epidemiologic Study of Early Renal Replacement Therapy after Orthotopic Liver Transplantation
Journal of the American Society of Nephrology
2002
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”